<DOC>
	<DOCNO>NCT00800358</DOCNO>
	<brief_summary>The purpose study determine whether oral paricalcitol safer efficacious compare oral calcitriol treatment hyperparathyroidism chronic kidney disease patient undergoing dialysis .</brief_summary>
	<brief_title>Safety Efficacy Study Paricalcitol Versus Calcitriol Treatment Secondary Hyperparathyroidism</brief_title>
	<detailed_description>Secondary hyperparathyroidism , common consequence chronic kidney disease , result abnormal regulation calcium phosphate homeostasis . The early administration calcium supplement vitamin D attenuate development progression hyperparathyroidism , prevent retard emergence many serious complication chronic kidney disease . However , vitamin D derivative also serious side effect , include hypercalcemia hyperphosphatemia , result , high level calcium-phosphate product . These adverse outcome prompt development novel , `` nonhypercalcemic '' vitamin D analogue . Three analogue recently market clinical use patient chronic kidney disease : 19-nor-1,25-dihydroxyvitamin D2 ( paricalcitol ) , 1 -hydroxyvitamin D2 ( doxercalciferol ) , 22-oxacalcitriol . Oral paricalcitol develop provide convenient , alternative therapy , particularly Peritoneal Dialysis patient regular intravenous administration paricalcitol practical . This study design determine proportion patient 'End stage renal failure ' haemodialysis peritoneal dialysis secondary hyperparathyroidism achieve 30 % reduction baseline iPTH concentration 24 week treatment Paricalcitol Calcitriol capsule .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism , Secondary</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<criteria>Age 18 year End stage renal disease regular maintenance haemodialysis peritoneal dialysis least 3 month iPTH level 300 pg/ml great baseline Written inform consent subject guardian Female patient either postmenopausal 2 year , surgically sterile childbearing age , use double contraception Baseline calcium value 2.87 mmol/L Baseline Ca x P great 5.63 mmol2/l2 Positive HBsAg Hepatitis C raise ALT twice upper limit normal evidence liver cirrhosis Clinically significant gastrointestinal disease History allergic reaction calcitriol vitamin D compound Inability unwillingness provide write consent . Inability unwillingness comply requirement protocol determined investigator . Pregnancy , breastfeed use nonreliable method contraception . Use medication prohibit prior randomization ketoconazole strong P450 3A inhibitor include atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir Necessity calcitonin , biphosphonates , maintenance oral intravenous glucocorticoid cinacalcet drug may affect calcium bone metabolism . Alcohol substance abuse within 6 month prior screen Other medical condition , investigator 's judgement , may associate increase risk subject may interfere study assessment outcomes . Participation another clinical trial and/or receipt investigational drug within 4 week prior screen visit . If PD subject active peritonitis within one month prior screen visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Secondary hyperparathyroidism</keyword>
	<keyword>End stage renal disease</keyword>
	<keyword>Haemodialysis</keyword>
	<keyword>Peritoneal dialysis</keyword>
	<keyword>Paricalcitol ( Zemplar )</keyword>
	<keyword>Calcitriol</keyword>
</DOC>